Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Trial Identifier: D6572C00001
Sponsor: AstraZeneca
NCTID:: NCT03276078
Start Date: November 2017
Primary Completion Date: June 2018
Study Completion Date: June 2018
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
Chinese Translation

Trial Locations

Country Location
China Changchun, China, 130021